1. Field of the Invention
Embodiments of the invention relate to an electrosurgical instrument coupled to a radiofrequency generator, and more particularly to an electrosurgical jaw structure that is capable of modulating ohmic heating of engaged tissue for tissue welding or sealing purposes.
2. Description of the Background Art
In the prior art, various energy sources such as radiofrequency (RF) sources, ultrasound sources and lasers have been developed to coagulate, seal or join together tissues volumes in open and laparoscopic surgeries. The most important surgical application relates to sealing blood vessels which contain considerable fluid pressure therein. In general, no instrument working ends using any energy source have proven reliable in creating a “tissue weld” or “tissue fusion” that has very high strength immediately post-treatment. For this reason, the commercially available instruments, typically powered by RF or ultrasound, are mostly limited to use in sealing small blood vessels and tissues masses with microvasculature therein. The prior art RF devices also fail to provide seals with substantial strength in anatomic structures having walls with irregular or thick fibrous content, in bundles of disparate anatomic structures, in substantially thick anatomic structures, or in tissues with thick fascia layers (e.g., large diameter blood vessels).
In a basic bi-polar RF jaw arrangement, each face of opposing first and second jaws comprises an electrode and RF current flows across the captured tissue between the opposing polarity electrodes. Such prior art RF jaws that engage opposing sides of tissue typically cannot cause uniform thermal effects in the tissue—whether the captured tissue is thin or substantially thick. As RF energy density in tissue increases, the tissue surface becomes desiccated and resistant to additional ohmic heating. Localized tissue desiccation and charring can occur almost instantly as tissue impedance rises, which then can result in a non-uniform seal in the tissue. The typical prior art RF jaws can cause further undesirable effects by propagating RF density laterally from the engaged tissue thus causing unwanted collateral thermal damage.
The commercially available RF sealing instruments typically use one of two approaches to “control” RF energy delivery in tissue. In a first “power adjustment” approach, the RF system controller can rapidly adjust the level of total power delivered to the jaws' engagement surfaces in response to feedback circuitry coupled to the active electrodes that measures tissue impedance or electrode temperature. In a second “current-path directing” approach, the instrument jaws carry an electrode arrangement in which opposing polarity electrodes are spaced apart by an insulator material—which may cause current to flow within an extended path through captured tissue rather that simply between surfaces of the first and second jaws. Electrosurgical grasping instruments having jaws with electrically-isolated electrode arrangements in cooperating jaws faces were proposed by Yates et al. in U.S. Pat. Nos. 5,403,312; 5,735,848 and 5,833,690.
The illustrations of the wall of a blood vessel in
Referring now to
Referring now to
This type of random, transient RF energy density in paths p through tissue, when any path may occur only for a microsecond interval, is not likely to uniformly denature proteins in the entire engaged tissue volume. It is believed that the “current-path directing” approach for tissue sealing can only accomplish tissue coagulation or seals with limited strength.
Various embodiments of systems and methods of the invention relate to creating thermal “welds” or “fusion” within native tissue volumes. The alternative terms of tissue “welding” and tissue “fusion” are used interchangeably herein to describe thermal treatments of a targeted tissue volume that result in a substantially uniform fused-together tissue mass, for example in welding blood vessels that exhibit substantial burst strength immediately post-treatment. The strength of such welds is particularly useful for (i) permanently sealing blood vessels in vessel transection procedures; (ii) welding organ margins in resection procedures; (iii) welding other anatomic ducts wherein permanent closure is required; and also (iv) for performing vessel anastomosis, vessel closure or other procedures that join together anatomic structures or portions thereof.
The welding or fusion of tissue as disclosed herein is to be distinguished from “coagulation”, “hemostasis” and other similar descriptive terms that generally relate to the collapse and occlusion of blood flow within small blood vessels or vascularized tissue. For example, any surface application of thermal energy can cause coagulation or hemostasis—but does not fall into the category of “welding” as the term is used herein. Such surface coagulation does not create a weld that provides any substantial strength in the treated tissue.
At the molecular level, the phenomena of truly “welding” tissue as disclosed herein may not be fully understood. However, the authors have identified the parameters at which tissue welding can be accomplished. An effective “weld” as disclosed herein results from the thermally-induced denaturation of collagen and other protein molecules in a targeted tissue volume to create a transient liquid or gel-like proteinaceous amalgam. A selected energy density is provided in the targeted tissue to cause hydrothermal breakdown of intra- and intermolecular hydrogen crosslinks in collagen and other proteins. The denatured amalgam is maintained at a selected level of hydration—without desiccation—for a selected time interval which can be very brief. The targeted tissue volume is maintained under a selected very high level of mechanical compression to insure that the unwound strands of the denatured proteins are in close proximity to allow their intertwining and entanglement. Upon thermal relaxation, the intermixed amalgam results in protein entanglement as re-crosslinking or renaturation occurs to thereby cause a uniform fused-together mass.
Various embodiments of the invention provide an electrosurgical jaw structure adapted for transecting captured tissue between the jaws and for contemporaneously welding the captured tissue margins with controlled application of RF energy. The jaw structure can comprise first and second opposing jaws that carry positive temperature coefficient (PTC) bodies for modulating RF energy delivery to the engaged tissue. In one embodiment the jaws can include first and second PTC bodies that define different temperature-impedance curves. Use of such first and second PTC bodies having different temperature impedance curves, allows for the control of the ohmic heating of tissue and the production of more uniform and higher strength welds than prior art RF sealing instruments
In one embodiment, the electrosurgical jaws use first and second energy-delivery jaw surfaces coupled in series to an RF source, with a first jaw surface overlying and electrically coupled to a first PTC body, wherein the first jaw surface and first PTC body are also coupled in parallel to the RF source. The second surface can overlie a second PTC body or a portion of the second surface can comprise the second PTC body.
In another embodiment, the electrosurgical jaws comprise an electrosurgical instrument that uses first and second jaws defining first and second energy-application surfaces. The first surface comprises a first polarity electrode portion and an electrically coupled PTC portion within a first circuit portion connected to an RF source. The second surface comprises a second polarity electrode and an electrically coupled PTC portion within a second circuit portion connected to the RF source, wherein the first and second circuit portions are parallel and series respectively.
1. Type “A” jaw structure for welding tissue.
As can be seen in
As can be seen in
In the embodiment of
In
In the exemplary embodiment of
It has been found that very high compression of tissue combined with controlled RF energy delivery is optimal for welding the engaged tissue volume contemporaneous with transection of the tissue. Preferably, the engagement gap g between the engagement planes ranges from about 0.0005″ to about 0.050″ for reducing the engaged tissue to the thickness of a membrane. More preferably, the gap between the tissue-engaging surfaces 155A and 155B ranges from about 0.001″ to about 0.005″.
Turning now to a discussion of the electrosurgical functionality of embodiments of the invention,
In
In a preferred embodiment, the PTC conductive-resistive matrix 160 is a variably resistive body that comprises a polypropylene or a medical grade silicone polymer that is doped with conductive particles (e.g. carbon). The novel use of PTC materials in electrosurgical working ends is described in co-pending U.S. patent application Ser. No. 10/351,449 filed Jan. 22, 2003 titled Electrosurgical Instrument and Method of Use (now U.S. Pat. No. 7,112,201); and Ser. No. 10/032,867 filed Oct. 22, 2001 titled Electrosurgical Jaw Structure for Controlled Energy Delivery (now U.S. Pat. No. 6,929,644), both of which are incorporated herein by reference. Polymer positive temperature coefficient (PTC) materials are known in the field of overcurrent protection devices that will “trip” and become resistant when a selected trip current is exceeded.
Various embodiments of PTC compositions can be fabricated from a non-conductive base polymer that is doped with conductive particles and exhibits two phases that define greater and lesser conductive properties. The first phase of the base polymer exhibits a crystalline or semi-crystalline state where the polymer molecules form long chains and are arranged in a more ordered architecture. When the temperature of the PTC is elevated, the polymer molecules maintain the crystalline architecture or structure—but eventually transition to an at least partly amorphous phase from the crystalline state. In the amorphous state, the molecules are aligned more randomly, and there typically is a slight increase in volume so that actual PTC geometry is altered. The non-conductive base polymer is combined with a dispersed, highly conductive particles, e.g., carbon nanoparticles to form a PTC matrix. In the crystalline phase of the polymer, the carbon particles are packed into the crystalline boundaries and form multiple conductive paths across the PTC. In this low temperature crystalline state, the polymer-carbon matrix is engineered to have a predetermined low resistance. For the purposes of the present invention, passive heat conduction from ohmically heated tissue can elevate the temperature of the PTC matrix. As long as the temperature increase in does not cause a phase change in the polymer, current will flow unimpeded. However, when the temperature of the PTC matrix is elevated to a selected temperature, called a switching range herein, the temperature will cause a phase change in the polymer. The crystalline structure of the polymer will disappear, and the carbon chains that allow for conduction across the PTC matrix will be broken resulting in an extraordinary increase in resistance. The polymer-carbon matrix can define a resistance measured in milliohms or ohms before the phase change. After the phase change, the PTC matrix' resistance can be measured in megaohms. Current flow can be reduced accordingly or terminated which is used to advantage in the present invention. Further, the modulation of current flow will be highly localized across the engagement surfaces of the PTC matrix.
In
It has been found that two differently performing PTC matrices 160 and 165 (
In contrast, the PTC matrix 160 in lower jaw 112A is designed to have a resistance vs. temperature characteristics with a much “higher” initial base resistance. The PTC matrix 160 maintains this “higher” base resistance over a similar temperature range as matrix 165. The PTC matrix indicated at PTC-160 in
In use, it can be understood that when tissue is engaged between the jaws (see
Thus, initial RF energy delivery to active conductor element 170 in
Referring now to
Referring now to
More in particular, the inventive jaw structure 100A clamped over tissue with RF delivery in one step contemporaneous with jaw closure and tissue transection. Prior art RF coagulation instruments in all cases (it is believed) use essentially three steps: (i) closing the jaw mechanism, (ii) applying RF energy to tissue, and (iii) actuating a blade member to transect the tissue. In contrast, the jaw structure of the present invention accomplishes all these functions in a single step. As can be understood from
It has been found that by applying RF energy by PTC modulated means as tissue is engaged and cut, the more proximal tissue is dehydrated to some extent as it is welded thus allowing the tissue to be easily compressed to a thin membrane. In
Thus, an embodiment of a method of the invention for welding tissue can include the microscale modulation of ohmic “active” heating in engaged tissue as depicted in
Referring now to
2. Type “B” electrosurgical system.
In
Although particular embodiments of the present invention have been described above in detail, it will be understood that this description is merely for purposes of illustration. Specific features of the invention are shown in some drawings and not in others, and this is for convenience only and any feature may be combined with another in accordance with the invention. Further, variations will be apparent to one skilled in the art in light of this disclosure and are intended to fall within the scope of the appended claims. Also, elements or steps from one embodiment can be readily recombined with one or more elements or steps from other embodiments.
This application is a division of U.S. application Ser. No. 11/673,889, filed Feb. 12, 2007 (now U.S. Pat. No. 7,381,209), which is a divisional of U.S. application Ser. No. 10/934,755, filed Sep. 3, 2004 (now U.S. Pat. No. 7,189,233), which claims the benefit of U.S. Provisional Application No. 60/500,746, filed on Sep. 4, 2003, and is a Continuation-in-part of U.S. patent application Ser. No. 10/351,449, filed Jan. 22, 2003, titled Electrosurgical Instrument and Method of Use (now U.S. Pat. No. 7,112,201), which claimed the benefit of Provisional Application Nos. 60/351,517, filed on Jan. 22, 2002, and 60/366, 992, filed on Mar. 20, 2002, and was a continuation-in-part of application Ser. No. 10/032,867 filed Oct. 22, 2001, titled Electrosurgical Jaw Structure for Controlled Energy Delivery (now U.S. Pat. No. 6,929,644); the full disclosures of which are incorporated herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
659409 | Mosher | Oct 1900 | A |
1586645 | Bierman | Jun 1926 | A |
1798902 | Raney | Mar 1931 | A |
1881250 | Tomlinson | Oct 1932 | A |
2031682 | Wappler et al. | Feb 1936 | A |
3651811 | Hildebrandt et al. | Mar 1972 | A |
3685518 | Beuerle et al. | Aug 1972 | A |
3730188 | Ellman | May 1973 | A |
3768482 | Shaw | Oct 1973 | A |
3826263 | Cage et al. | Jul 1974 | A |
4092986 | Schneiderman | Jun 1978 | A |
4198957 | Cage et al. | Apr 1980 | A |
4219025 | Johnson | Aug 1980 | A |
4231371 | Lipp | Nov 1980 | A |
4232676 | Herczog | Nov 1980 | A |
4271838 | Lasner et al. | Jun 1981 | A |
4353371 | Cosman | Oct 1982 | A |
4370980 | Lottick | Feb 1983 | A |
4375218 | Digeronimo | Mar 1983 | A |
4492231 | Auth | Jan 1985 | A |
4590934 | Malis et al. | May 1986 | A |
4608981 | Rothfuss et al. | Sep 1986 | A |
4633874 | Chow et al. | Jan 1987 | A |
4654511 | Horsma et al. | Mar 1987 | A |
4655216 | Tischer | Apr 1987 | A |
4671274 | Sorochenko | Jun 1987 | A |
4691703 | Auth et al. | Sep 1987 | A |
4763669 | Jaeger | Aug 1988 | A |
4785807 | Blanch | Nov 1988 | A |
4848337 | Shaw et al. | Jul 1989 | A |
4850353 | Stasz et al. | Jul 1989 | A |
4887612 | Esser et al. | Dec 1989 | A |
4940468 | Petillo | Jul 1990 | A |
4958539 | Stasz et al. | Sep 1990 | A |
4969885 | Farin | Nov 1990 | A |
4985030 | Melzer et al. | Jan 1991 | A |
5009656 | Reimels | Apr 1991 | A |
5057106 | Kasevich et al. | Oct 1991 | A |
5057107 | Parins et al. | Oct 1991 | A |
5085659 | Rydell | Feb 1992 | A |
5104025 | Main et al. | Apr 1992 | A |
5122137 | Lennox | Jun 1992 | A |
5147356 | Bhatta | Sep 1992 | A |
5147357 | Rose et al. | Sep 1992 | A |
5151102 | Kamiyama et al. | Sep 1992 | A |
5190541 | Abele et al. | Mar 1993 | A |
5201900 | Nardella | Apr 1993 | A |
5207691 | Nardella | May 1993 | A |
5258006 | Rydell et al. | Nov 1993 | A |
5267998 | Hagen | Dec 1993 | A |
5269780 | Roos | Dec 1993 | A |
5290286 | Parins | Mar 1994 | A |
5306280 | Bregen et al. | Apr 1994 | A |
5308311 | Eggers et al. | May 1994 | A |
5324289 | Eggers | Jun 1994 | A |
5336221 | Anderson | Aug 1994 | A |
5360428 | Hutchinson, Jr. | Nov 1994 | A |
5364389 | Anderson | Nov 1994 | A |
5389098 | Tsuruta et al. | Feb 1995 | A |
5403312 | Yates et al. | Apr 1995 | A |
5417687 | Nardella et al. | May 1995 | A |
5443463 | Stern et al. | Aug 1995 | A |
5445638 | Rydell et al. | Aug 1995 | A |
5451224 | Goble et al. | Sep 1995 | A |
5458598 | Feinberg et al. | Oct 1995 | A |
5480397 | Eggers et al. | Jan 1996 | A |
5480398 | Eggers | Jan 1996 | A |
5507106 | Fox | Apr 1996 | A |
5531744 | Nardella et al. | Jul 1996 | A |
5571153 | Wallsten | Nov 1996 | A |
5573535 | Viklund | Nov 1996 | A |
5593406 | Eggers et al. | Jan 1997 | A |
5611798 | Eggers | Mar 1997 | A |
5624452 | Yates | Apr 1997 | A |
5674220 | Fox et al. | Oct 1997 | A |
5693051 | Schulze et al. | Dec 1997 | A |
5716366 | Yates | Feb 1998 | A |
5735848 | Yates et al. | Apr 1998 | A |
5755717 | Yates et al. | May 1998 | A |
5766166 | Hooven | Jun 1998 | A |
5776130 | Buysse et al. | Jul 1998 | A |
5797938 | Paraschal et al. | Aug 1998 | A |
5800449 | Wales | Sep 1998 | A |
5807392 | Eggers | Sep 1998 | A |
5833690 | Yates et al. | Nov 1998 | A |
5891142 | Eggers et al. | Apr 1999 | A |
5911719 | Eggers | Jun 1999 | A |
5947984 | Whipple | Sep 1999 | A |
6019758 | Slater | Feb 2000 | A |
6030384 | Nezhat | Feb 2000 | A |
6039733 | Buysse et al. | Mar 2000 | A |
6074389 | Levine et al. | Jun 2000 | A |
6086586 | Hooven | Jul 2000 | A |
6113598 | Baker | Sep 2000 | A |
6132426 | Kroll | Oct 2000 | A |
6139508 | Simpson et al. | Oct 2000 | A |
6152923 | Ryan | Nov 2000 | A |
6162220 | Nezhat | Dec 2000 | A |
6174309 | Wrublewski et al. | Jan 2001 | B1 |
6176857 | Ashley | Jan 2001 | B1 |
6179834 | Buysse et al. | Jan 2001 | B1 |
6179835 | Panescu et al. | Jan 2001 | B1 |
6179837 | Hooven | Jan 2001 | B1 |
6187003 | Buysse et al. | Feb 2001 | B1 |
6190386 | Rydell | Feb 2001 | B1 |
6193709 | Miyawaki et al. | Feb 2001 | B1 |
6270497 | Sekino et al. | Aug 2001 | B1 |
6273887 | Yamauchi et al. | Aug 2001 | B1 |
6277117 | Tetzlaff et al. | Aug 2001 | B1 |
6296640 | Wampler et al. | Oct 2001 | B1 |
6298550 | Kirwan, Jr. | Oct 2001 | B1 |
6328703 | Murakami | Dec 2001 | B1 |
6334861 | Chandler et al. | Jan 2002 | B1 |
6350264 | Hooven | Feb 2002 | B1 |
6352536 | Buysse et al. | Mar 2002 | B1 |
6398779 | Buysse et al. | Jun 2002 | B1 |
6409725 | Khandkar et al. | Jun 2002 | B1 |
6451018 | Lands et al. | Sep 2002 | B1 |
6458128 | Schulze | Oct 2002 | B1 |
6458130 | Frazier et al. | Oct 2002 | B1 |
6464704 | Schmaltz | Oct 2002 | B2 |
6468275 | Wampler et al. | Oct 2002 | B1 |
6492629 | Sopory | Dec 2002 | B1 |
6500176 | Truckai et al. | Dec 2002 | B1 |
6511480 | Tetzlaff et al. | Jan 2003 | B1 |
6527767 | Wang et al. | Mar 2003 | B2 |
6533784 | Truckai et al. | Mar 2003 | B2 |
6554829 | Schulze et al. | Apr 2003 | B2 |
6575968 | Eggers et al. | Jun 2003 | B1 |
6585735 | Frazier et al. | Jul 2003 | B1 |
6632193 | Davison et al. | Oct 2003 | B1 |
6652521 | Schulze | Nov 2003 | B2 |
6656177 | Truckai et al. | Dec 2003 | B2 |
6773409 | Truckai et al. | Aug 2004 | B2 |
6802843 | Truckai et al. | Oct 2004 | B2 |
6843789 | Goble | Jan 2005 | B2 |
6890332 | Truckai et al. | May 2005 | B2 |
6893435 | Goble | May 2005 | B2 |
6913579 | Truckai et al. | Jul 2005 | B2 |
6926716 | Baker et al. | Aug 2005 | B2 |
6929644 | Truckai et al. | Aug 2005 | B2 |
7011657 | Truckai et al. | Mar 2006 | B2 |
7041102 | Truckai et al. | May 2006 | B2 |
7083619 | Truckai et al. | Aug 2006 | B2 |
7112201 | Truckai et al. | Sep 2006 | B2 |
7189233 | Truckai et al. | Mar 2007 | B2 |
7309849 | Truckai et al. | Dec 2007 | B2 |
20020177848 | Truckai et al. | Nov 2002 | A1 |
20030018327 | Truckai et al. | Jan 2003 | A1 |
20030050635 | Truckai et al. | Mar 2003 | A1 |
20030078573 | Truckai et al. | Apr 2003 | A1 |
20030114851 | Truckai et al. | Jun 2003 | A1 |
20030139741 | Goble et al. | Jul 2003 | A1 |
Number | Date | Country |
---|---|---|
0 341 446 | Apr 1989 | EP |
0 517 244 | Mar 1996 | EP |
0 518 230 | May 1996 | EP |
2536924 | Jun 1984 | FR |
2647683 | Dec 1990 | FR |
2037167 | Jul 1980 | GB |
2066104 | Jul 1981 | GB |
2133290 | Apr 1989 | GB |
2161082 | Mar 1996 | GB |
05-337129 | Dec 1993 | JP |
10-033551 | Feb 1998 | JP |
10-118092 | May 1998 | JP |
2001-057302 | Feb 2001 | JP |
2001-170069 | Jun 2001 | JP |
342617 | Jun 1984 | SU |
575103 | May 1996 | SU |
WO 9424951 | Jul 1980 | WO |
WO 9424949 | Jul 1981 | WO |
WO 9308754 | May 1993 | WO |
Number | Date | Country | |
---|---|---|---|
20080188851 A1 | Aug 2008 | US |
Number | Date | Country | |
---|---|---|---|
60500746 | Sep 2003 | US | |
60351517 | Jan 2002 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 11673889 | Feb 2007 | US |
Child | 12098560 | US | |
Parent | 10934755 | Sep 2004 | US |
Child | 11673889 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 10351449 | Jan 2003 | US |
Child | 10934755 | US | |
Parent | 10032867 | Oct 2001 | US |
Child | 10351449 | US |